Peer-reviewed veterinary case report
Serum clusterin levels linked to lymphoma in dogs
By McNaught, Katie A. et al.·Published in Veterinary and Comparative Oncology·2019·Small Animal Hospital, School of Veterinary Medicine, College of Medical Veterinary and Life Sciences University of Glasgow Glasgow UK, United Kingdom·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Preliminary assessment of serum clusterin as a potential biomarker for canine lymphoma
- Species:
- dog
Plain-English summary
A study looked at serum clusterin levels in dogs with multicentric lymphoma, a type of cancer that affects the lymph nodes. Researchers found that dogs with this lymphoma had significantly lower levels of clusterin compared to healthy dogs. However, once the lymphoma dogs were treated and went into remission, their clusterin levels were similar to those before treatment, making it unclear if clusterin could be a reliable marker for this cancer. More research is needed to determine if clusterin can help predict outcomes for dogs with lymphoma.
People also search for: dog lymphoma treatment · canine cancer biomarkers · low clusterin levels in dogs
Abstract
AbstractClusterin (CLU), also known as apolipoprotein J, is a widely expressed, heterodimeric, glycoprotein, important in tumourigenesis, apoptosis and immunoregulation. In humans, CLU expression has been associated with anaplastic large cell and Hodgkin's lymphoma. In this study, serum CLU levels in dogs with multicentric lymphoma (MLSA) were compared with healthy control dogs, using both western blot and enzyme‐linked immunosorbent assay (ELISA). Western blot confirmed the presence of CLU in dog sera at the predicted molecular weight and the relative levels detected correlated with the levels detected by ELISA. CLU level analysis by ELISA found treatment naïve dogs with MLSA had a significantly (P < .001) lower serum CLU level compared with healthy controls. However, there was no significant difference between MLSA dogs prior to treatment and in complete remission. The wide variation in serum CLU levels may limit its potential as a single candidate biomarker for MLSA, although any prognostic predictive value of serum CLU concentrations has yet to be assessed.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12550